DK1699797T3 - Pyrrolotriazinforbindelser som kinasehæmmere - Google Patents

Pyrrolotriazinforbindelser som kinasehæmmere

Info

Publication number: DK1699797T3
Authority: DK; Denmark
Prior art keywords: kinase inhibitors; pyrrolotriazine compounds; pyrrolotriazine; compounds; kinase
Prior art date: 2003-12-29

Application number

DK04815269T

Other languages

English (en)

Inventor

Brian E Fink

Ashvinikumar V Gavai

Gregory D Vite

Ping Chen

Harold Mastalerz

Derek J Norris

John S Tokarski

Yufen Zhao

Wen-Ching Han

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-29

Filing date

2004-12-23

Publication date

2010-01-04

2004-12-23 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2010-01-04 Application granted granted Critical

2010-01-04 Publication of DK1699797T3 publication Critical patent/DK1699797T3/da

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000003921 pyrrolotriazines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK04815269T 2003-12-29 2004-12-23 Pyrrolotriazinforbindelser som kinasehæmmere DK1699797T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53333503P	2003-12-29	2003-12-29
PCT/US2004/043169 WO2005066176A1 (en)	2003-12-29	2004-12-23	Pyrrolotriazine compounds as kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK1699797T3 true DK1699797T3 (da)	2010-01-04

Family

ID=34748887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04815269T DK1699797T3 (da)	2003-12-29	2004-12-23	Pyrrolotriazinforbindelser som kinasehæmmere

Country Status (31)

Country	Link
US (4)	US7141571B2 (da)
EP (2)	EP2058314A1 (da)
JP (1)	JP4740878B2 (da)
KR (1)	KR100839716B1 (da)
CN (1)	CN1922182B (da)
AR (1)	AR047076A1 (da)
AT (1)	ATE443706T1 (da)
AU (1)	AU2004312413C1 (da)
BR (1)	BRPI0418231A (da)
CA (1)	CA2552107C (da)
CL (1)	CL2009001492A1 (da)
CY (1)	CY1109662T1 (da)
DE (1)	DE602004023324D1 (da)
DK (1)	DK1699797T3 (da)
ES (1)	ES2331842T3 (da)
GE (1)	GEP20105081B (da)
HR (1)	HRP20090601T1 (da)
IL (1)	IL176450A0 (da)
MX (1)	MXPA06007038A (da)
MY (1)	MY145634A (da)
NO (1)	NO20062763L (da)
NZ (2)	NZ573544A (da)
PE (1)	PE20050679A1 (da)
PL (1)	PL1699797T3 (da)
PT (1)	PT1699797E (da)
RU (1)	RU2373209C2 (da)
SI (1)	SI1699797T1 (da)
TW (1)	TWI332840B (da)
UA (1)	UA89038C2 (da)
WO (1)	WO2005066176A1 (da)
ZA (1)	ZA200605160B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6867300B2 (en) *	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
EP1497019B1 (en) *	2002-04-23	2015-05-20	Bristol-Myers Squibb Company	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US20060014741A1 (en) *	2003-12-12	2006-01-19	Dimarco John D	Synthetic process, and crystalline forms of a pyrrolotriazine compound
MY145634A (en) *	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US20050288290A1 (en) *	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) *	2004-06-30	2006-01-01	Bristol Myers Squibb Co	A method for preparing pyrrolotriazine compounds
US7504521B2 (en) *	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en)	2004-08-12	2006-06-16	Bristol Myers Squibb Co	Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
TW200635927A (en) *	2004-12-22	2006-10-16	Bristol Myers Squibb Co	Synthetic process
US7358256B2 (en)	2005-03-28	2008-04-15	Bristol-Myers Squibb Company	ATP competitive kinase inhibitors
US20060235020A1 (en) *	2005-04-18	2006-10-19	Soojin Kim	Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
MY150958A (en)	2005-06-16	2014-03-31	Astrazeneca Ab	Compounds for the treatment of multi-drug resistant bacterial infections
US8338594B2 (en) *	2005-12-02	2012-12-25	Bayer Healthcare Llc	Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
US8063208B2 (en) *	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US20100136137A1 (en) *	2006-11-01	2010-06-03	Bristol-Meyers Squibb Company	Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound
KR101502634B1 (ko)	2007-02-08	2015-03-16	코덱시스, 인코포레이티드	케토 환원 효소 및 이의 용도
US20090076034A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched bms-690514
CA2704125A1 (en) *	2007-12-19	2009-07-09	Genentech, Inc.	8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
JP2010209058A (ja) *	2008-09-29	2010-09-24	Sumitomo Chemical Co Ltd	１−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
EP2344504B1 (en) *	2008-10-08	2014-06-04	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
EP2376491B1 (en)	2008-12-19	2015-03-04	Cephalon, Inc.	Pyrrolotriazines as alk and jak2 inhibitors
CA2750047A1 (en)	2009-01-21	2010-07-29	Basilea Pharmaceutica Ag	Novel bicyclic antibiotics
TW201107328A (en) *	2009-07-28	2011-03-01	Daiichi Sankyo Co Ltd	Pyrrolo [2,3-d] pyrimidine derivatives
TWI510241B (zh)	2010-02-18	2015-12-01	Vtv Therapeutice Llc	苯基－雜芳基衍生物及其使用方法
KR101789129B1 (ko)	2010-06-30	2017-11-20	후지필름 가부시키가이샤	신규 니코틴아미드 유도체 또는 그 염
CN102153558B (zh) *	2011-02-23	2012-11-21	扬州永济医药新技术有限公司	多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法
DE102011119127A1 (de) *	2011-11-22	2013-05-23	Merck Patent Gmbh	3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9724352B2 (en)	2012-05-31	2017-08-08	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh)	2012-05-31	2016-08-17	中国科学院上海药物研究所	吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
TW201414737A (zh)	2012-07-13	2014-04-16	必治妥美雅史谷比公司	作爲激酶抑制劑之咪唑并三□甲腈
WO2015054358A1 (en)	2013-10-11	2015-04-16	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
SMT202400142T1 (it) *	2014-01-13	2024-05-14	Aurigene Oncology Ltd	Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
EP3143392B1 (en) *	2014-05-12	2023-02-22	Quest Diagnostics Investments Incorporated	Quantitation of tamoxifen metabolites by mass spectrometry
AR112027A1 (es)	2017-06-15	2019-09-11	Biocryst Pharm Inc	Inhibidores de alk 2 quinasa que contienen imidazol
US12030897B2 (en)	2018-05-08	2024-07-09	Medshine Discovery Inc.	Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof
EP4424312A3 (en)	2019-04-12	2025-01-08	Blueprint Medicines Corporation	Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
WO2021088987A1 (zh) *	2019-11-08	2021-05-14	南京明德新药研发有限公司	作为选择性her2抑制剂的盐型、晶型及其应用
MX2023002233A (es)	2020-08-24	2023-03-15	Gilead Sciences Inc	Compuestos fosfolipidos y usos de estos.
US20240132521A1 (en) *	2022-08-22	2024-04-25	Iambic Therapeutics, Inc.	Compounds and methods for modulating her2
US20250345339A1 (en) *	2024-02-20	2025-11-13	Iambic Therapeutics, Inc.	Doses and regimens of her2 inhibitors
CN121202763A (zh) *	2025-06-12	2025-12-26	成都道合尔医药技术有限公司	(3r,4r)-n-pg-4-氨基-3-甲基哌啶及其中间体的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ283281B6 (cs) *	1992-09-25	1998-02-18	Eli Lilly And Company	Způsob přípravy v poloze 5 substituovaných pyrrolo(2,3-d)pyrimidinů
CA2163399A1 (en)	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
TR199900389T2 (xx)	1996-08-28	2000-06-21	Pfizer Inc.	�kame edilmi� 6,5-hetero-bisiklik t�revleri.
US6982265B1 (en)	1999-05-21	2006-01-03	Bristol Myers Squibb Company	Pyrrolotriazine inhibitors of kinases
CZ303660B6 (cs) *	1999-05-21	2013-02-13	Bristol-Myers Squibb Company	Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
US6787545B1 (en)	1999-08-23	2004-09-07	Shiongi & Co., Ltd.	Pyrrolotriazine derivatives having spla2-inhibitory activities
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en)	2000-11-17	2003-12-30	Bristol-Myers Squibb Company	Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
KR100847605B1 (ko)	2000-11-17	2008-07-21	브리스톨-마이어스스퀴브컴파니	ｐ38 키나제 관련 질병의 치료 방법 및 키나제 억제제로서유용한 피롤로트리아진 화합물
TW200300350A (en)	2001-11-14	2003-06-01	Bristol Myers Squibb Co	C-5 modified indazolylpyrrolotriazines
JP2005529890A (ja) *	2002-04-23	2005-10-06	ブリストル−マイヤーズ　スクイブ　カンパニー	キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
EP1497019B1 (en)	2002-04-23	2015-05-20	Bristol-Myers Squibb Company	Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US6894066B2 (en)	2002-05-09	2005-05-17	Bernard Charles Sherman	Magnesium salt of S-omeprazole
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
US6933386B2 (en)	2002-07-19	2005-08-23	Bristol Myers Squibb Company	Process for preparing certain pyrrolotriazine compounds
WO2004013145A1 (en)	2002-08-02	2004-02-12	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
TW200420565A (en)	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
US7064203B2 (en) *	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) *	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7102003B2 (en) *	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7151176B2 (en)	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds

2004
- 2004-12-09 MY MYPI20045093A patent/MY145634A/en unknown
- 2004-12-22 TW TW093140035A patent/TWI332840B/zh not_active IP Right Cessation
- 2004-12-22 US US11/019,901 patent/US7141571B2/en not_active Expired - Lifetime
- 2004-12-23 KR KR1020067012936A patent/KR100839716B1/ko not_active Expired - Fee Related
- 2004-12-23 NZ NZ573544A patent/NZ573544A/en unknown
- 2004-12-23 CN CN2004800421984A patent/CN1922182B/zh not_active Expired - Fee Related
- 2004-12-23 BR BRPI0418231-6A patent/BRPI0418231A/pt not_active IP Right Cessation
- 2004-12-23 GE GEAP20049544A patent/GEP20105081B/en unknown
- 2004-12-23 DK DK04815269T patent/DK1699797T3/da active
- 2004-12-23 CA CA2552107A patent/CA2552107C/en not_active Expired - Fee Related
- 2004-12-23 SI SI200431286T patent/SI1699797T1/sl unknown
- 2004-12-23 PL PL04815269T patent/PL1699797T3/pl unknown
- 2004-12-23 HR HR20090601T patent/HRP20090601T1/hr unknown
- 2004-12-23 UA UAA200608400A patent/UA89038C2/ru unknown
- 2004-12-23 WO PCT/US2004/043169 patent/WO2005066176A1/en not_active Ceased
- 2004-12-23 ES ES04815269T patent/ES2331842T3/es not_active Expired - Lifetime
- 2004-12-23 EP EP09153694A patent/EP2058314A1/en not_active Withdrawn
- 2004-12-23 NZ NZ548070A patent/NZ548070A/en unknown
- 2004-12-23 DE DE602004023324T patent/DE602004023324D1/de not_active Expired - Lifetime
- 2004-12-23 JP JP2006547328A patent/JP4740878B2/ja not_active Expired - Fee Related
- 2004-12-23 AT AT04815269T patent/ATE443706T1/de active
- 2004-12-23 MX MXPA06007038A patent/MXPA06007038A/es active IP Right Grant
- 2004-12-23 EP EP04815269A patent/EP1699797B1/en not_active Expired - Lifetime
- 2004-12-23 PT PT04815269T patent/PT1699797E/pt unknown
- 2004-12-23 RU RU2006127396/04A patent/RU2373209C2/ru not_active IP Right Cessation
- 2004-12-23 AU AU2004312413A patent/AU2004312413C1/en not_active Ceased
- 2004-12-29 AR ARP040104947A patent/AR047076A1/es not_active Application Discontinuation
2005
- 2005-01-03 PE PE2005000015A patent/PE20050679A1/es not_active Application Discontinuation
2006
- 2006-06-13 NO NO20062763A patent/NO20062763L/no not_active Application Discontinuation
- 2006-06-20 IL IL176450A patent/IL176450A0/en unknown
- 2006-06-22 ZA ZA200605160A patent/ZA200605160B/en unknown
- 2006-06-26 US US11/426,479 patent/US7297695B2/en not_active Expired - Lifetime
2008
- 2008-09-24 US US11/869,910 patent/US7846931B2/en not_active Expired - Lifetime
2009
- 2009-06-26 CL CL2009001492A patent/CL2009001492A1/es unknown
- 2009-12-21 CY CY20091101326T patent/CY1109662T1/el unknown
2010
- 2010-10-25 US US12/911,299 patent/US20110039838A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7141571B2 (en)	2006-11-28
CA2552107A1 (en)	2005-07-21
GEP20105081B (en)	2010-09-27
HRP20090601T1 (hr)	2009-12-31
NZ548070A (en)	2009-02-28
CN1922182A (zh)	2007-02-28
US20050182058A1 (en)	2005-08-18
TW200526226A (en)	2005-08-16
MY145634A (en)	2012-03-15
PT1699797E (pt)	2009-12-29
ZA200605160B (en)	2007-12-27
US20090048244A1 (en)	2009-02-19
US20060264438A1 (en)	2006-11-23
HK1088332A1 (en)	2006-11-03
KR20060107828A (ko)	2006-10-16
NZ573544A (en)	2010-04-30
AU2004312413C1 (en)	2011-01-27
US7297695B2 (en)	2007-11-20
US20110039838A1 (en)	2011-02-17
CY1109662T1 (el)	2014-08-13
NO20062763L (no)	2006-09-11
JP2007518721A (ja)	2007-07-12
CN1922182B (zh)	2010-08-18
EP2058314A1 (en)	2009-05-13
CL2009001492A1 (es)	2010-01-15
RU2006127396A (ru)	2008-02-10
BRPI0418231A (pt)	2007-04-27
ES2331842T3 (es)	2010-01-18
SI1699797T1 (sl)	2010-04-30
JP4740878B2 (ja)	2011-08-03
EP1699797B1 (en)	2009-09-23
EP1699797A1 (en)	2006-09-13
ATE443706T1 (de)	2009-10-15
MXPA06007038A (es)	2006-08-31
AU2004312413B2 (en)	2010-07-22
IL176450A0 (en)	2006-10-05
DE602004023324D1 (de)	2009-11-05
CA2552107C (en)	2011-10-18
PE20050679A1 (es)	2005-09-25
WO2005066176A1 (en)	2005-07-21
PL1699797T3 (pl)	2010-02-26
US7846931B2 (en)	2010-12-07
UA89038C2 (en)	2009-12-25
TWI332840B (en)	2010-11-11
AR047076A1 (es)	2006-01-04
KR100839716B1 (ko)	2008-06-19
RU2373209C2 (ru)	2009-11-20
AU2004312413A1 (en)	2005-07-21

Publication	Publication Date	Title
ATE443706T1 (de)	2009-10-15	Pyrrolotriazinverbindungen als kinaseinhibitoren
DK1585749T3 (da)	2008-09-22	Diazepinoindol-derivater som kinaseinhibitorer
NO20055680D0 (no)	2005-12-01	Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK2039685T3 (da)	2013-03-25	Heterobicycliske forbindelser som P38-inhibitorer
DK1720882T3 (da)	2011-04-11	Pyrazolopyrimidin-derivater som cyclin-afhængige kinaseinhibitorer
NO20044560L (no)	2004-11-10	Pyrrolotriazin anilin forbindelser nyttige som kinase inhibitorer
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
DE602004025258D1 (de)	2010-03-11	Aminotriazol-verbindungen als proteinkinase-hemmer
DK1603570T3 (da)	2013-05-21	Aminoheteroarylforbindelser som proteinkinaseinhibitorer
IS7534A (is)	2004-11-16	Pýrazóló-pýrimídín anilín efnasambönd, gagnleg sem kínasatálmar
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
DK1605897T3 (da)	2012-08-20	Polyethelen-glycol-link-glp-1-forbindelser
IS8108A (is)	2005-10-31	Ný efnasambönd
DK1711481T4 (da)	2013-08-26	Krystallinsk monohydrat som kinaseinhibitorer
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1660090T3 (da)	2012-12-17	Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
DE60311768D1 (de)	2007-03-29	Axiallüftereinheit
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
IS8228A (is)	2006-01-11	Ný asetídínefnasambönd
DE602004026905D1 (de)	2010-06-10	2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
EP1778693A4 (en)	2009-11-11	AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
IS8089A (is)	2005-10-25	Efnasambönd
IS8292A (is)	2006-02-09	Ný efnasambönd
NO20031736D0 (no)	2003-04-15	Forbindelser